Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review [PDF]
Pharmaceuticals, 2023 Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi.
Adwoa Dansoa Tabi-Amponsah +5 more
doaj +7 more sources
Variation in serum urate levels in the absence of gout and urate lowering therapy [PDF]
BMC Rheumatology, 2021 Background Previous studies have noted significant variation in serum urate (sUA) levels, and it is unknown how this influences the accuracy of hyperuricemia classification based on single data points.
Andrew Shaffer +4 more
doaj +5 more sources
Treatment approaches and adherence to urate-lowering therapy for patients with gout [PDF]
Patient Preference and Adherence, 2017 Thanda Aung,* Gihyun Myung,* John D FitzGerald Division of Rheumatology/Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA *These authors contributed equally to this work Abstract: Gout is the most common ...
Aung T, Myung G, FitzGerald JD
doaj +8 more sources
Spinal gout recovery with urate‐lowering therapy: A case report [PDF]
Clinical Case ReportsKey Clinical Message The occurrence of spinal gout resulting in erosion of the superior articular process in patients with low back pain is uncommon, potentially leading to misdiagnosis and inappropriate treatment.
Kunfang Huo +5 more
doaj +4 more sources
Urate-lowering therapy and kidney function
Современная ревматология, 2023 Chronic hyperuricemia (CH) and gout are independent risk factors for decreased kidney function. In the last decade, evidence was accumulating that urate-lowering therapy may be an effective method of slowing down the progression of CH and gout-mediated ...
M. S. Eliseev
doaj +2 more sources
Urate-lowering therapy for patients with gout on hemodialysis. [PDF]
Int J Rheum Dis, 2022 AbstractObjectiveGout is the most common form of inflammatory arthritis and is caused by deposition of monosodium urate crystals resulting from a high burden of uric acid (UA). High UA burden also has been associated with increased morbidity and mortality in the general population and progression to chronic kidney disease.
Alkilany R, Einstadter D, Antonelli M.
europepmc +3 more sources
Urate-lowering therapy for heart failure
Современная ревматология, 2019 Heart failure (HF) is one of the major public health problems in developed countries. Hyperuricemia (HU) is often found in patients with chronic HF (CHF) and is a well-known independent predictor for mortality and re-hospitalization for the progression ...
O. V. Zhelyabina, M. S. Eliseev
doaj +3 more sources
Revisiting the Ethics of Urate-Lowering Therapy Clinical Trials for Gout Management. [PDF]
Arthritis RheumatolArthritis &Rheumatology, Volume 78, Issue 8, Page 1632-1635, August 2026.
Stamp LK, Ho D, Dalbeth N.
europepmc +2 more sources
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol [PDF]
International Journal for Equity in Health, 2021 Background Gout is a painful chronic disease which disrupts work and family life and can lead to chronic joint damage. Pacific people in Aotearoa/New Zealand experience significant inequities, with over three times the gout prevalence of the non-Pacific ...
Malakai Ofanoa +8 more
doaj +2 more sources
Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. [PDF]
Arthritis Rheumatol, 2023 ObjectiveUsing trial data comparing treat‐to‐target allopurinol and febuxostat in gout, we examined participant characteristics associated with serum urate (SU) goal achievement.MethodsParticipants with gout and SU ≥6.8 mg/dL were randomized to allopurinol or febuxostat, titrated during weeks 0 to 24, and maintained weeks 25 to 48.
Helget LN +13 more
europepmc +3 more sources